Recon: FDA’s increased use of clinical holds; BioNTech buys AI startup InstaDeep for up to $682M

• U.S. experts recommend weight-loss drugs for obese children (Reuters)
• Abbvie raises sales outlook of two immunology drugs to more than $17.5 bln in 2025 (Reuters)
• Sen. Sanders asks Moderna not to hike COVID vaccine price (Reuters) (STAT)
• FDA’s Califf says congressional report on Aduhelm controversy contained “no surprises” (STAT)
• FDA Increasingly Halting Human Trials as Companies Pursue Risky, Cutting-Edge Drugs (WSJ)
• An FDA pathway to clear medical devices is putting patients at risk, research suggests (STAT)
• Illumina, the DNA sequencing giant, gives Wall Street bad news (STAT)
• Most Alzheimer’s patients would pay up to $26,500 per year for new treatment Leqembi (CNBC)

• Germany's BioNTech buys British AI startup InstaDeep (Reuters) (FT)
• Illumina challenges EU order to keep Grail separate (Reuters)
• Bayer flags new blood thinner as $5 bln-plus opportunity (Reuters)
• Pfizer CEO rules out generic COVID drug Paxlovid for China (Reuters)
• Free access to Zolgensma curbed, says Novartis (PharmaPhorum)

• Private equity acquires a taste for drug development (Reuters)
• People hate drug ads on TV. Here’s what they complain about most (STAT)
• FDA commissioner calls for more onshoring of clinical trials (Endpoints)
• US Funding Law Could Speed Approval Of Drugs And Biologics Manufactured In Advanced Ways (Pink Sheet)
• US FDA’s Use Of CRLs Hit A High Note In 2022: One-Third Of Novel Agent Decisions Were Not Approvals (Pink Sheet)
• CVS Is Exploring a $10 Billion-Plus Acquisition of Oak Street Health (Bloomberg)
• Shenzhen Kangtai Biological sees 2022 net loss on weaker COVID shot demand (Reuters)
• Novotech's latest acquisitions grow its US presence and plant a European foothold (Endpoints)
• Alto’s hopes for brain biomarker strategy rise on phase 2 antidepressant data (Fierce)
• Fierce Biotech Layoff Tracker 2023: Editas edits workforce, plus more (Fierce)
• JPM23: Mirati's post-Krazati pipeline restock to focus on 'highest opportunity for capital' (Fierce)
• Voyager goes big, securing multi-billion dollar gene therapy development deal with Neurocrine (Endpoints)
• Ionis sells partial stake in royalties from Spinraza and Novartis cardio drug to Royalty Pharma for $500M upfront (Endpoints)
• AbbVie, following in footsteps of Lilly and Takeda, pays Anima $42M to go after undruggable targets (Fierce)
• Jasper scraps pivotal plans but adds a new indication as more biotechs revise pipelines (Endpoints)
• 4D Molecular pauses enrollment in Fabry trials after kidney problems in three patients (Endpoints)
• Sutro shells out latest update on ovarian cancer treatment, plans for pivotal trial (Endpoints)

• GE HealthCare expects 5%-7% organic revenue growth in 2023 on strong demand (Reuters)
• Medtronic CEO Martha: No more divestitures planned for 2023, but review continues (MedtechDive)
• UK To Fund ‘Artificial Pancreas’ Technology, But Only For Companies That Cut Prices (MedtechInsight)
• ResMed responds to ‘humanitarian emergency’ over demand for CPAP devices with new factory (MedtechDive)
• Beta Bionics hires Harvard diabetes expert as CMO ahead of artificial pancreas launch (MedtechDive)
• JPM23: 'What has the pandemic done for us?' Freenome and other diagnostics developers on making tests more accessible (Fierce)

• Still fuming over the federal Covid response, Republicans redirect the House coronavirus committee (STAT)
• Teva's opioid settlement moves forward with participation from 48 states (Endpoints)
• U.S. appeals court won't revive Zofran birth defect cases against GSK (Reuters)
• Jet Medical and Related Companies Agree to Pay More Than $700,000 to Resolve Medical Device Allegations (FDA)